Alto Neuroscience (ANRO) EPS (Basic) (2023 - 2026)

Alto Neuroscience has reported EPS (Basic) for 4 years, with the latest figure at -$0.79 in Q1 2026.

• Quarterly EPS (Basic) fell 35.54% year-over-year to -$0.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.13 (down 2843.29% YoY) and the FY2025 annual result came in at -$3.88, up 1.79% from the prior year.
• EPS (Basic) retreated to -$0.79 in Q1 2026 per ANRO's latest filing, from -$0.53 in the prior quarter.
• Over five years, EPS (Basic) peaked at -$0.53 in Q4 2025 and troughed at -$68.38 in Q3 2025.
• A 4-year average of -$7.44 and a median of -$0.79 in 2026 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2024 and 2025: EPS (Basic) soared 79.37% in 2024, then plunged 10915.86% in 2025.
• Over 4 years, EPS (Basic) stood at -$2.93 in 2023, then jumped by 79.37% to -$0.6 in 2024, then climbed by 12.48% to -$0.53 in 2025, then slumped by 50.21% to -$0.79 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.79, -$0.53, and -$68.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.